Yazar "Gunesacar, Ramazan" seçeneğine göre listele

Listeleniyor 1 - 4 / 4
  • [ X ]
    Öğe
    Effect of serum adropin levels on circulating endothelial dysfunction biomarkers in COVID-19 patients
    (2023) Gunesacar, Ramazan; Eksi, Durkadin Demir; Alpay, Ali Seydi; Hanikoglu, Ferhat; Erdogan, Haluk
    Purpose: Several studies show that the symptoms of severe COVID-19 infection reflect the clinical phenotype of endothelial dysfunction and share common pathophysiological mechanisms with endothelial dysfunction. Therefore, the aim of the study was to investigate the effect of serum adropin levels on endothelial dysfunction biomarkers and determine whether adropin could be a new biomarker for COVID-19. Materials and Methods: The study included 40 patients with mild/moderate COVID-19, 48 patients with severe/critical COVID-19, and 37 controls. Serum adropin and circulating biomarkers of endothelial dysfunction including asymmetric dimethylarginine (ADMA), endothelin-1 (ET-1), endothelial nitric oxide synthase (eNOS), soluble intercellular adhesion molecule-1 (sICAM-1) and plasminogen activator inhibitor-1 (PAI-1) levels were determined by micro-ELISA. Results: Serum adropin levels were found to be significantly higher in COVID-19 patients (165.2±11.49 pg/ml) than in controls (85.46±12.08 pg/ml). Serum adropin levels of patients with severe/critical symptoms (194±16.23 pg/ml) were significantly higher than the patients with mild/moderate symptoms (130.6 ±14.53). In addition, serum ADMA, eNOS, and, ET-1 levels were significantly higher in the COVID-19 subjects (150.5±8.67 ng/ml, 172.4±14.01 pg/ml, 159.3±10.19 pg/ml, respectively) than that those in the controls (104.5±9.182 ng/ml, 141.4±17.74 pg/ml, 100.1±11.37 pg/ml, respectively). Significant positive correlations were found between adropin and ADMA, eNOS, ET-1, sICAM-1, and PAI-1 levels in the patients. Conclusion: We suggest that adropin may be a new potential biomarker for COVID-19 and an important molecule in restoring endothelial cell damage. Positive correlations between serum adropin levels and ADMA, eNOS, ET-1, sICAM-1 and PAI-1 levels in patients suggest that adropin may compensate for damage to endothelial cells.
  • [ X ]
    Öğe
    Effect of serum adropin levels on circulating endothelial dysfunction biomarkers in COVID-19 patients
    (Cukurova Univ, Fac Medicine, 2023) Gunesacar, Ramazan; Eksi, Durkadin Demir; Alpay, Ali Seydi; Hanikoglu, Ferhat; Erdogan, Haluk
    Purpose: Several studies show that the symptoms of severe COVID-19 infection reflect the clinical phenotype of endothelial dysfunction and share common pathophysiological mechanisms with endothelial dysfunction. Therefore, the aim of the study was to investigate the effect of serum adropin levels on endothelial dysfunction biomarkers and determine whether adropin could be a new biomarker for COVID-19.Materials and Methods: The study included 40 patients with mild/moderate COVID-19, 48 patients with severe/critical COVID-19, and 37 controls. Serum adropin and circulating biomarkers of endothelial dysfunction including asymmetric dimethylarginine (ADMA), endothelin-1 (ET-1), endothelial nitric oxide synthase (eNOS), soluble intercellular adhesion molecule-1 (sICAM-1) and plasminogen activator inhibitor-1 (PAI-1) levels were determined by micro-ELISA. Results: Serum adropin levels were found to be significantly higher in COVID-19 patients (165.2 & PLUSMN;11.49 pg/ml) than in controls (85.46 & PLUSMN;12.08 pg/ml). Serum adropin levels of patients with severe/critical symptoms (194 & PLUSMN;16.23 pg/ml) were significantly higher than the patients with mild/moderate symptoms (130.6 & PLUSMN;14.53). In addition, serum ADMA, eNOS, and, ET-1 levels were significantly higher in the COVID-19 subjects (150.5 & PLUSMN;8.67 ng/ml, 172.4 & PLUSMN;14.01 pg/ml, 159.3 & PLUSMN;10.19 pg/ml, respectively) than that those in the controls (104.5 & PLUSMN;9.182 ng/ml, 141.4 & PLUSMN;17.74 pg/ml, 100.1 & PLUSMN;11.37 pg/ml, respectively). Significant positive correlations were found between adropin and ADMA, eNOS, ET-1, sICAM-1, and PAI-1 levels in the patients. Conclusion: We suggest that adropin may be a new potential biomarker for COVID-19 and an important molecule in restoring endothelial cell damage. Positive correlations between serum adropin levels and ADMA, eNOS, ET-1, sICAM-1 and PAI-1 levels in patients suggest that adropin may compensate for damage to endothelial cells.
  • [ X ]
    Öğe
    Elevated Blood Levels of VEGF Exhibiting Positive Correlation with HIF-1? in Obesity: A Single Center Study
    (2025) Uluergüven, Nazmiye; Eksi, Durkadin Demir; Maytalman, Erkan; Gunesacar, Ramazan
    Aim: The objective of this study was to investigate the relevance of plasma hypoxia-inducible factor-1 alpha (HIF-1?) and vascular endothelial growth factor (VEGF) levels in obesity and their associations with body mass index (BMI), body fat percentage, and waist to-hip ratio. Material and Methods: The study included 45 obese subjects and 28 healthy controls recruited from a private clinic in Manavgat, Antalya. The measurement of BMI, percentage of body fat, and waist-to-hip ratio was conducted in all subjects using a bioelectrical impedance analysis device. The plasma levels of HIF-1? and VEGF were measured using the micro-ELISA method. Results: In the Mann-Whitney U test, HIF-1? levels were similar in obese subjects (median=1.439 ng/L [Interquartile range (IQR)=11.62, min-max=0.904-12.53] and control group (median=1.377 ng/L [1.323, 0.852-2.175], p=0.0821). VEGF levels were found to be significantly higher in obese subjects compared to the controls (medians; 729.8 ng/L [5515, 485.3-6000] vs. 589.5 ng/L, [416.8, 396.4-813.2], respectively, p
  • [ X ]
    Öğe
    The Role of Energy Homeostasis-Associated Gene Expression and Serum Adropin Levels in Patients with Familial Mediterranean Fever
    (Mdpi, 2025) Eksi, Durkadin Demir; Duran, Gulay Gulbol; Celik, Muhammet Murat; Eksi, Yunus Emre; Gunesacar, Ramazan
    Familial Mediterranean Fever (FMF) is a genetic autoinflammatory disease primarily affecting populations in the Mediterranean region. The pathogenesis of FMF and the roles of various molecules remain unclear. Adropin, a protein encoded by the Energy Homeostasis-Associated Gene (ENHO), is involved in energy metabolism and inflammation. This study aimed to explore the relationship between ENHO expression, Adropin levels, and FMF, examining their correlations with disease characteristics. This study included 30 patients clinically diagnosed with FMF and 35 healthy controls. The ENHO expression in peripheral blood mononuclear cells was assessed using a qRT-PCR, and the serum Adropin levels were measured via ELISA. The ENHO expression was significantly elevated in the FMF patients compared to the controls (p = 0.0007), while no significant differences were observed in the serum Adropin levels between the groups (p = 0.81). A correlation analysis revealed a negative association between the ENHO expression and age (r = -0.47, p = 0.009), whereas the serum Adropin levels were positively correlated with age, disease onset, and diagnostic delay (p < 0.05). No significant associations were found between the ENHO expression and Adropin levels or FMF clinical features. These findings suggest that increased ENHO expression may play a role in FMF pathophysiology, potentially as a compensatory mechanism. The correlation between Adropin levels and disease onset indicates a potential protective role. Further studies are needed to confirm these findings.